TABLE 2

 Lists of US FDA-approved personalized oncological medications during 2012–2017

Data comes from www.fda.gov/drugs.

Drug NameCompanyActive IngredientApproval DateIndicationBiomarkers
VerzenioEli LillyAbemaciclib09/28/2017Breast cancerHR+ and HER2-
IdhifaCelgeneEnasidenib08/01/2017Acute myeloid leukemia (AML)IDH2 mutation
NerlynxPuma BiotechnologyNeratinib07/17/2017Breast cancerHER2-amplified
RydaptNovartisMidostaurin04/28/2017AMLFLT3+
AlunbrigTakedaBrigatinib04/28/2017Non-small cell lung cancer (NSCLC)ALK+
ZejulaTesaroNiraparib03/27/2017Recurrent epithelial ovarian, fallopian tube,  or primary peritoneal cancerBRCA1, BRCA2
KisqaliNovartisRibociclib03/14/2017Metastatic breast cancerHR+, HER2-
ImfinziAstraZenecaDurvalumab03/01/2017Metastatic urothelial carcinomaPD-L1
RubracaClovis OncologyRucaparib12/19/2016Ovarian cancerBRCA1, BRCA2
LartruvoEli LillyOlaratumab10/19/2016Soft tissue sarcomaPDGFRA+
TecentriqGenentechAtezolizumab5/18/2016Bladder cancerPD-L1
VenclextaAbbVie and GenentechVenetoclax4/11/2016Chronic lymphocytic leukemia (CML)17p-deleption
AlecensaRoche and GenentechAlectinib12/11/2015Metastatic NSCLCALK
CotellicGenentechCobimetinib11/10/2015Metastatic melanomaBRAF-V600E/K
UnituxinUnited TherapeuticsDinutuximab3/10/2015NeuroblastomaMYCN-amplification
TagrissoAstraZenecaOsimertinib11/13/2015NSCLCEGFR-T790M
IbrancePfizerPalbociclib2/3/2015Metastatic breast cancerER+/HR+, HER2-
OpdivoBristol-Myers SquibbNivolumab12/22/2014Metastatic melanomaBRAF-V600
LynparzaAstraZenecaOlaparib12/19/2014Metastatic ovarian cancerBRCA1, BRCA2
KeytrudaMerckPembrolizumab9/4/2014Metastatic melanomaPD-L1 positive
ZykadiaNovartisCeritinib4/29/2014Metastatic NSCLCALK+
ImbruvicaJanssenIbrutinib11/13/2013Mantle cell lymphoma (MCL)17p-deleption
GazyvaGenentechObinutuzumab11/1/2013Chronic lymphocytic leukemia (CLL)MS4A1 (CD20+)
GilotrifBoehringer IngelheimAfatinib7/12/2013Metastatic NSCLCEGFR
TafinlarGlaxoSmithKlineDabrafenib5/29/2013Metastatic melanomaBRAF-V600E/K
MekinistGlaxoSmithKlineTrametinib5/29/2013Metastatic melanomaBRAF-V600E/K
KadcylaGenentechAdo-trastuzumab  emtansine2/22/2013Metastatic breast cancerHER2+
IclusigAriad PharmaceuticalsPonatinib12/14/2012CMLBCR-ABL1, T315I
CometriqExelixisCabozantinib11/29/2012Medullary thyroid cancerRET
SynriboTeva PharmaceuticalOmacetaxine  mepesuccinate10/26/2012CMLBCR-ABL1
BosulifPfizerBosutinib9/4/2012CMLBCR-ABL1
PerjetaGenentechPertuzumab6/8/2012Metastatic breast cancerHER2+
  • ALK, anaplastic lymphoma kinase; BRCA, breast cancer; FLT3, fms like tyrosine kinase 3; HR+, hormone receptor-positive; MS4A1, membrane spanning 4-domains A1; MYCN, N-myc proto-oncogene protein; PDGFRA, platelet-derived growth factor receptor A; RET, ret proto-oncogene.